NFX vs. EVG, MTFB, DEST, ROQ, VAL, BSFA, RENE, SALV, OVB, and ONC
Should you be buying Nuformix stock or one of its competitors? The main competitors of Nuformix include Evgen Pharma (EVG), Motif Bio (MTFB), Destiny Pharma (DEST), Roquefort Therapeutics (ROQ), ValiRx (VAL), BSF Enterprise (BSFA), ReNeuron Group (RENE), SalvaRx Group (SALV), Ovoca Bio (OVB), and Oncimmune (ONC). These companies are all part of the "biotechnology" industry.
Nuformix vs.
Evgen Pharma (LON:EVG) and Nuformix (LON:NFX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, community ranking, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.
Evgen Pharma received 124 more outperform votes than Nuformix when rated by MarketBeat users. Likewise, 74.23% of users gave Evgen Pharma an outperform vote while only 66.99% of users gave Nuformix an outperform vote.
Evgen Pharma has a beta of 1.44, meaning that its share price is 44% more volatile than the S&P 500. Comparatively, Nuformix has a beta of 1.22, meaning that its share price is 22% more volatile than the S&P 500.
27.8% of Evgen Pharma shares are held by institutional investors. Comparatively, 0.1% of Nuformix shares are held by institutional investors. 32.4% of Evgen Pharma shares are held by insiders. Comparatively, 12.4% of Nuformix shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Nuformix's return on equity of -5.68% beat Evgen Pharma's return on equity.
Nuformix is trading at a lower price-to-earnings ratio than Evgen Pharma, indicating that it is currently the more affordable of the two stocks.
Nuformix has a consensus target price of GBX 293, indicating a potential upside of 314,953.76%. Given Nuformix's stronger consensus rating and higher probable upside, analysts plainly believe Nuformix is more favorable than Evgen Pharma.
In the previous week, Evgen Pharma had 1 more articles in the media than Nuformix. MarketBeat recorded 1 mentions for Evgen Pharma and 0 mentions for Nuformix. Nuformix's average media sentiment score of 0.00 beat Evgen Pharma's score of -0.84 indicating that Nuformix is being referred to more favorably in the news media.
Summary
Nuformix beats Evgen Pharma on 8 of the 15 factors compared between the two stocks.
Get Nuformix News Delivered to You Automatically
Sign up to receive the latest news and ratings for NFX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nuformix Competitors List
Related Companies and Tools
This page (LON:NFX) was last updated on 3/31/2025 by MarketBeat.com Staff
